Cardiome Pharma CRME
-
Placing Cardiome Under Review
We are placing our fair value estimate for Cardiome CRME under review while we re-evaluate our expectations ..... vernakalant, we think it is increasingly unlikely that Cardiome will regain control of the product.
-
Putting Cardiome Under Review as Oral Vernakalant is Abandoned by Merck
We are placing shares of Cardiome CRME under review and plan to significantly lower ..... oral vernakalant is still uncertain, as Cardiome does not yet know if Merck will return the asset to Cardiome or if it will hold on to it, but the drug …
-
Shares of Cardiome Pharma ([[ CRME ]] -43%) plunge after announcing Merck (MRK) will stop development of its oral vernakalant, which was being evaluated as maintenance therapy for the long-term ...
Shares of Cardiome Pharma ( CRME -43% ) plunge after announcing Merck ( MRK ) will stop development of its oral vernakalant, which was being evaluated as maintenance therapy for the long-term prevention of atrial fibrillation recurrence. Post your comment!
-
Cardiome Pharma ([[ CRME ]] -7%) gets hit after Wedbush cuts the shares to Neutral, citing concern over continued delays in the Phase 3 trials for oral Vernakalant by its partner Merck.
Cardiome Pharma ( CRME -7% ) gets hit after Wedbush cuts the shares to Neutral, citing concern over continued delays in the Phase 3 trials for oral Vernakalant by its partner Merck. Post your comment!
-
'Beat Up' Biotechs To Buy: Part 1
By StockMarketPundits : Investing in biotech stocks can be hazardous to your financial health, or in the alternate they may provide a miracle cure to the FMV of your portfolio. Our thought has always been to research the group, “cherry pick” your favorites and then buy a basket of them. The ...
-
UPDATE 2- Cardiome reports loss as revenue drops
TORONTO, Aug 8 (Reuters) - Cardiome Pharma Corp on Monday reported a quarterly net loss as revenue tumbled and research and development costs rose.
-
UPDATE 1- Cardiome reports loss as revenue drops
TORONTO, Aug 8 (Reuters) - Cardiome Pharma Corp on Monday reported a quarterly net loss as revenue tumbled and research and development costs rose.
-
Canadian drug developer Cardiome Pharma ( CRME ) surges 23.5% after announcing it has given consent for the transfer of North American rights for the development and commercialization of its ...
Canadian drug developer Cardiome Pharma ( CRME ) surges 23.5% after announcing it has given consent for ..... fibrillation drug from Astellas ( ALPMY.PK ) to Merck ( MRK ). Cardiome releases earnings after the close today. Post your comment …
-
Sanofi ([[SNY]] +0.5%) discontinues Phase III trials of its atrial fibrillation drug Multaq, leaving competitor Cardiome's ([[ CRME ]] +2.5%) own recently approved oral antiarrhythmic Vernakalant open ...
Sanofi ( SNY +0.5% ) discontinues Phase III trials of its atrial fibrillation drug Multaq, leaving competitor Cardiome 's ( CRME +2.5% ) own recently approved oral antiarrhythmic Vernakalant open to gain market share. Post your comment!
-
Benefit by Imitating Julian Robertson: Bullish on Commodities, China, And Tech
Insider Monkey submits: Earlier this month Julian Robertson commented about Fed’s monetary policy, budget deficits, and global economy. Robertson said the U.S. isn’t doing enough to address structural problems, such as budget deficits in its economy. “"We prefer to put on the Santa Claus suit and